Avinash Venkatanarayan
About Avinash Venkatanarayan
Avinash Venkatanarayan is a Principal Scientist at Bristol Myers Squibb in Cambridge, Massachusetts, with a strong background in cancer biology and a robust publication record.
Company
Avinash Venkatanarayan currently works at Bristol Myers Squibb in Cambridge, Massachusetts, United States. He holds dual roles as Principal Scientist and Research Investigator II. Bristol Myers Squibb is a global biopharmaceutical company known for its innovative medicine in oncology, cardiovascular, and immunology.
Title
Avinash Venkatanarayan is Principal Scientist and Research Investigator II at Bristol Myers Squibb. In these roles, he focuses on early target discovery and validation, working towards developing novel therapies for undruggable cancer pathways.
Education and Expertise
Avinash Venkatanarayan earned a Doctor of Philosophy (Ph.D.) in Cancer Biology from UT MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, where he studied from 2009 to 2015. He also holds a Master of Science in Molecular Biotechnology from The University of Texas at San Antonio, completed between 2007 and 2009. Earlier, he obtained a Bachelor of Technology in Industrial Biotechnology & Chemical Engineering from Anna University from 2003 to 2007. His expertise includes developing and utilizing Genetically Engineered Mouse Models (GEMMs) for cancer research.
Background
Avinash Venkatanarayan has a rich background in biomedical research. Before joining Bristol Myers Squibb, he worked for five years at Genentech, Inc as a Post-Doctoral Research Scientist. Prior to that, he served as a Graduate Research Assistant at UT MD Anderson Cancer Center for six years. He also has experience as a Graduate Research and Teaching Assistant at The University of Texas at San Antonio, spanning two years.
Achievements
Avinash Venkatanarayan has published research in major scientific journals such as Nature and Cancer Cell. His work primarily focuses on cancer biology, particularly in early target discovery and validation for developing novel therapies. His contributions to the field include the use of GEMMs in cancer research. Avinash aims to be a leader in the realm of early target discovery and validation, driven by his passion for curiosity-driven science.